Actively Recruiting
Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)
Led by Paul Szabolcs · Updated on 2026-05-15
25
Participants Needed
1
Research Sites
39 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating hematopoietic stem cell transplantation (HSCT) with a reduced-intensity conditioning regimen including total body irradiation for people diagnosed with Common Variable Immunodeficiency (CVID) and other autoimmune manifestations of Primary Immune Regulatory Disorders (PIRD). This Phase II, open-label study focuses on correcting inheritable immune defects in patients aged 5 to 40 years. Genetic screening is required to identify relevant immune deficiencies such as CID, IPEX syndrome, and others. Participants will receive an allogenic stem cell transplant from a related or unrelated donor matched fully or partially by human leukocyte antigen (HLA). The conditioning regimen includes alemtuzumab/Campath, anti-thymocyte globulin, fludarabine, melphalan, and total body irradiation. Graft sources include bone marrow or mobilized peripheral blood stem cells. After the transplant, subjects are monitored for two years following standard care practices. During the study, participants will undergo regular evaluations including chimerism testing at multiple time points up to 24 months, immune function assessments such as immunoglobulin levels, and monitoring for graft-versus-host disease. The primary outcome is survival two years after transplant. Secondary outcomes include immune cell engraftment, immunoglobulin independence, and incidence of acute and chronic graft-versus-host disease. Safety and function are closely followed throughout the study period.
CONDITIONS
Brief Title
Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Written informed consent from patient, parent, or legal guardian; assent if developmentally able
- Male or female aged 5 through 40 years at consent
- Evidence of CVID or autoimmune manifestation of a primary immune regulatory disorder confirmed by genetic screening
- Failure or intolerance to mycophenolate mofetil and a B cell-depleting antibody like Rituximab
- Glomerular Filtration Rate (GFR) ≥ 50 mL/min/1.73 m2
- Aspartate Aminotransferase (AST) ≤ 4 times upper limit of normal
- Alanine Aminotransferase (ALT) ≤ 4 times upper limit of normal
- Direct bilirubin ≤ 2.5 mg/dL
- Negative HIV by serology and PCR
- Negative HTLV by serology
- Cardiac ejection fraction ≥ 40% or shortening fraction ≥ 26%
- Forced Vital Capacity (FVC) and Forced Expiratory Volume in 1 second (FEV1) ≥ 40% predicted for age
- Peripheral Capillary Oxygen Saturation (SpO2) > 92% at rest on room air
- At least 8 weeks post-solid organ transplant before conditioning, if applicable
- Negative pregnancy test for females over 10 years old or post-menarche unless surgically sterilized
- Agreement to use FDA-approved birth control for females of childbearing potential and sexually active males for up to 12 months post-transplant or while on harmful medications
- Informed of infertility risks and advised on sperm or oocyte preservation
- Transplant endorsement from a clinical immunologist
You will not qualify if you...
- Allergy to Dimethylsulfoxide (DMSO) or ingredients in the stem cell product
- Uncontrolled systemic infection
- Receipt of any live attenuated vaccine within 4 weeks prior to transplant
- Medical problems or findings that increase risk or interfere with study compliance as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single transplant procedure with conditioning period
Participants receive a hematopoietic stem cell transplant (HSCT) with a conditioning regimen including alemtuzumab/Campath, anti-thymocyte globulin, Fludarabine, Melphalan, and total body irradiation.
1 transplant visit and immediate post-transplant care
Duration - 2 years
Participants are followed for 2 years after transplant per standard of care practices to monitor survival, engraftment, immune reconstitution, graft-versus-host disease, and other outcomes.
Multiple visits over 2 years including assessments at 1, 2, 3, 6, 12, 18, and 24 months post-transplant
Trial Site Locations
Total: 1 location
1
UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15224
Actively Recruiting
Research Team
S
Shawna A McIntyre, RN
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here